US FDA’s Drug Shortage Program On ‘Site Engagement’ To Be Nixed In GDUFA III
Executive Summary
Generics industry and FDA also debated inspection policies in lieu of travel and safety restrictions mandated by the pandemic.
You may also be interested in...
GDUFA III Talks Completed
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.
Forty-Eight US FDA Drug Application Decisions Delayed By Pandemic's Deferred Inspections
US FDA 'resilience' report charts how inspection backlog grew and impacted approvals and compliance follow-up.
FDA Avoided Half Of ANDA Pre-Approval Inspections During COVID By Using Alternative Tools
Records reviews are common now in lieu of an in-person inspection for US generic applications, but more virtual facility checks could be coming soon.